Literature DB >> 19224553

Extracellular and intracellular mechanisms that mediate the metastatic activity of exogenous osteopontin.

Jami Mandelin1, Emme C K Lin, Dana D Hu, Susan K Knowles, Kim-Anh Do, Xuemei Wang, E Helene Sage, Jeffrey W Smith, Wadih Arap, Renata Pasqualini.   

Abstract

BACKGROUND: Osteopontin affects several steps of the metastatic cascade. Despite direct correlation with metastasis in experimental systems and in patient studies, the extracellular and intracellular basis for these observations remains unsolved. In this study, the authors used human melanoma and sarcoma cell lines to evaluate the effects of soluble osteopontin on metastasis.
METHODS: Exogenous osteopontin or negative controls, including a site-directed mutant osteopontin, were used in functional assays in vitro, ex vivo, and in vivo that were designed to test the extracellular and intracellular mechanisms involved in experimental metastasis.
RESULTS: In the extracellular environment, the results confirmed that soluble osteopontin is required for its prometastatic effects; this phenomenon is specific, arginine-glycine-aspartic acid (RGD)-dependent, and evident in experimental models of metastasis. In the intracellular environment, osteopontin initially induced rapid tyrosine 418 (Tyr-418) dephosphorylation of the cellular homolog of the Rous sarcoma virus (c-Src), with decreases in actin stress fibers and increased binding to the vascular endothelium. This heretofore undescribed Tyr dephosphorylation was followed by a tandem c-Src phosphorylation after tumor cell attachment to the metastatic site.
CONCLUSIONS: The results of this study revealed a complex molecular interaction as well as a dual role for osteopontin in metastasis that depends on whether tumor cells are in circulation or attached. Such context-dependent functional insights may contribute to antimetastasis strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224553      PMCID: PMC2743165          DOI: 10.1002/cncr.24170

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  45 in total

1.  ERM proteins regulate cytoskeleton relaxation promoting T cell-APC conjugation.

Authors:  Sophie Faure; Laura Inés Salazar-Fontana; Monique Semichon; Victor L J Tybulewicz; Georges Bismuth; Alain Trautmann; Ronald N Germain; Jérôme Delon
Journal:  Nat Immunol       Date:  2004-02-01       Impact factor: 25.606

2.  Binding of soluble form of fibroblast surface protein, fibronectin, to collagen.

Authors:  E Engvall; E Ruoslahti
Journal:  Int J Cancer       Date:  1977-07-15       Impact factor: 7.396

3.  CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis.

Authors:  Y U Katagiri; J Sleeman; H Fujii; P Herrlich; H Hotta; K Tanaka; S Chikuma; H Yagita; K Okumura; M Murakami; I Saiki; A F Chambers; T Uede
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

4.  Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence.

Authors:  A Oldberg; A Franzén; D Heinegård
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

5.  Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12.

Authors:  Hidemi Teramoto; Maria Domenica Castellone; Renae L Malek; Noah Letwin; Bryan Frank; J Silvio Gutkind; Norman H Lee
Journal:  Oncogene       Date:  2005-01-13       Impact factor: 9.867

6.  Variants of the cell recognition site of fibronectin that retain attachment-promoting activity.

Authors:  M D Pierschbacher; E Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

7.  Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells.

Authors:  Riku Das; Ganapati H Mahabeleshwar; Gopal C Kundu
Journal:  J Biol Chem       Date:  2004-01-02       Impact factor: 5.157

8.  Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival.

Authors:  H Singhal; D S Bautista; K S Tonkin; F P O'Malley; A B Tuck; A F Chambers; J F Harris
Journal:  Clin Cancer Res       Date:  1997-04       Impact factor: 12.531

9.  A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells.

Authors:  M J Humphries; K Olden; K M Yamada
Journal:  Science       Date:  1986-07-25       Impact factor: 47.728

10.  Systemic endocrine instigation of indolent tumor growth requires osteopontin.

Authors:  Sandra S McAllister; Ann M Gifford; Ashley L Greiner; Stephen P Kelleher; Matthew P Saelzler; Tan A Ince; Ferenc Reinhardt; Lyndsay N Harris; Bonnie L Hylander; Elizabeth A Repasky; Robert A Weinberg
Journal:  Cell       Date:  2008-06-13       Impact factor: 41.582

View more
  3 in total

1.  Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas.

Authors:  Daniëlle Verver; Vichnou Poirier-Colame; Gorana Tomasic; Khadija Cherif-Rebai; Dirk J Grunhagen; Cornelis Verhoef; Stefan Suciu; Caroline Robert; Laurence Zitvogel; Alexander M M Eggermont
Journal:  Oncoimmunology       Date:  2019-09-06       Impact factor: 8.110

2.  Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells.

Authors:  Antje Hahnel; Henri Wichmann; Matthias Kappler; Matthias Kotzsch; Dirk Vordermark; Helge Taubert; Matthias Bache
Journal:  Radiat Oncol       Date:  2010-09-17       Impact factor: 3.481

3.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.